Rosiglitazone Add-On in Treatment of Depressed Patients with Insulin Resistance: a Pilot Study

Rosiglitazone Add-On in Treatment of Depressed Patients with Insulin Resistance: a Pilot Study

A number of cross-sectional studies have suggested an association between insulin resistance (IR) and affective disorders. However, limited data exist on potential changes in IR in a prospective treatment of depression. The present pilot study tested the hypothesis that improvement of IR with the ad...

Full description

Saved in:

Bibliographic Details
Main Authors:	Natalie L. Rasgon, Heather A. Kenna, Katherine E. Williams, Bevin Powers, Tonita Wroolie, Alan F. Schatzberg
Format:	Article
Language:	English
Published:	Wiley 2010-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1100/tsw.2010.32
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of the Effectiveness of Insulin Sensitizing Agents Metformin and Rosiglitazone in PCOS
by: Rıfat Emral, et al.
Published: (2008-06-01)

Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression—A Pilot Study
by: Daniel Szawarnoga, et al.
Published: (2025-07-01)

Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats
by: Jia Li, et al.
Published: (2018-01-01)

Effects of Metformin-Rosiglitazone on Glucose, Coagulation and Fibrinolysis among Diabetics
by: *Okungbowa, M. A. O. and Oyegue O. K.
Published: (2017-09-01)

RP-HPLC Method for the Simultaneous Estimation of Rosiglitazone and Gliclazide in Tablets
by: G. Rathinavel, et al.
Published: (2009-01-01)

Pilot Trial of Hydroxychloroquine as Add-On Therapy in Patients With Membranous Nephropathy
by: Hongyu Yang, et al.
Published: (2024-12-01)

Coordinate Transcriptomic and Metabolomic Effects of the Insulin Sensitizer Rosiglitazone on Fundamental Metabolic Pathways in Liver, Soleus Muscle, and Adipose Tissue in Diabetic db/db Mice
by: Sabrina Le Bouter, et al.
Published: (2010-01-01)

Rosiglitazone Improves Glucocorticoid Resistance in a Sudden Sensorineural Hearing Loss by Promoting MAP Kinase Phosphatase-1 Expression
by: Liang Xia, et al.
Published: (2019-01-01)

Retraction: Rosiglitazone exerts an anti-depressive effect in unpredictable chronic mild-stress-induced depressive mice by maintaining essential neuron autophagy and inhibiting excessive astrocytic apoptosis
by: Frontiers Editorial Office
Published: (2025-07-01)

Protective effect of rosiglitazone on early renal interstitial damage induced by CsA
by: CHENG Gen-yang, et al.
Published: (2015-01-01)

European Medicines Agency (EMA) announces termination of Avandia (rosiglitazone usage in Europe)
by: Inna Igorevna Klefortova
Published: (2010-09-01)

Is It Necessary to Add the Feedback Insufflation Time in Manikins? A Simulation Pilot Study
by: Luis Castro-Alonso, et al.
Published: (2024-08-01)

Prenatal Rosiglitazone Administration to Neonatal Rat Pups Does Not Alter the Adult Metabolic Phenotype
by: Hernan Sierra, et al.
Published: (2012-01-01)

Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
by: Giulia Cantini, et al.
Published: (2008-01-01)

12. Topical Rosiglitazone Improves Fibrosis and Enhances Adipogenesis in Radiation-induced Skin Injury
by: Ashley E. Siegel, MD, et al.
Published: (2025-05-01)

Manual of clinical psychopharmacology /
by: Schatzberg, Alan F.
Published: (1986)

Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects
by: Renata Bocciardi, et al.
Published: (2010-01-01)

CGKRK-targeted lipid nanoparticles enhance in vivo rosiglitazone delivery to the placenta to ameliorate murine preeclampsia
by: Ke Li, et al.
Published: (2025-08-01)

Perceived Neighborhood Social Environment and Adolescent Depressive Symptoms: Insights from the Add Health
by: Rachel J. Kulchar, et al.
Published: (2024-12-01)

Association Between Four Non-Insulin-Based Insulin Resistance Indices and the Risk of Post-Stroke Depression
by: Wang P, et al.
Published: (2025-01-01)

An Updated Systematic Review and Meta‐Analysis on the Efficacy and Safety of Metformin as Add‐on Therapy to Insulin in Patients With Type 1 Diabetes
by: Mohammad Mahdi Masouri, et al.
Published: (2025-07-01)

Fluid Retention Caused by Rosiglitazone Is Related to Increases in AQP2 and αENaC Membrane Expression
by: Jinghua Xu, et al.
Published: (2017-01-01)

The Impact of Chronic Kidney Disease and Short-Term Treatment with Rosiglitazone on Plasma Cell-Free DNA Levels
by: Amanda L. McGuire, et al.
Published: (2014-01-01)

The Novel Oral Drug Subetta Exerts an Antidiabetic Effect in the Diabetic Goto-Kakizaki Rat: Comparison with Rosiglitazone
by: Danielle Bailbé, et al.
Published: (2013-01-01)

The Effectiveness of Add-on Treatment with Nutraceutical
by: V. T. Ivashkin, et al.
Published: (2022-08-01)

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
by: Heng Wan, et al.
Published: (2016-01-01)

Association among obesity, insulin resistance, and depressive symptoms: a mediation analysis
by: Guoqiang Xiao, et al.
Published: (2025-04-01)

Add-On Therapy with Ertapenem in Infections with Multidrug Resistant Gram-Negative Bacteria: Pediatric Experience
by: Sevgen Tanır Basaranoglu, et al.
Published: (2017-01-01)

Dual Modulation of Adipogenesis and Apoptosis by PPARG Agonist Rosiglitazone and Antagonist Betulinic Acid in 3T3-L1 Cells
by: Patsawee Sriboonaied, et al.
Published: (2025-05-01)

Rosiglitazone Affects Nitric Oxide Synthases and Improves Renal Outcome in a Rat Model of Severe Ischemia/Reperfusion Injury
by: Boris Betz, et al.
Published: (2012-01-01)

Optical vortices in add-drop filters
by: B.P. Lapin, et al.
Published: (2025-06-01)

Add-on Lamotrigine Treatment for Subsyndromal Depression after Manic or Mixed States in Bipolar Disorder Improved the Quality of Life
by: Katsumasa Muneoka, et al.
Published: (2012-01-01)

Activation of Peroxisome Proliferator-Activated Receptor γ by Rosiglitazone Inhibits Lipopolysaccharide-Induced Release of High Mobility Group Box 1
by: Jung Seok Hwang, et al.
Published: (2012-01-01)

Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial.
by: Roel J T Mocking, et al.
Published: (2012-01-01)

Reslizumab as add-on therapy in patients with refractory asthma
by: J Christian Virchow, et al.
Published: (2020-09-01)

Liver enzyme levels in adolescents with obesity and insulin resistance: a commentary
by: Katherine Ning-Li
Published: (2024-01-01)

Impact of Yoga Practice on Lipid Profile and Insulin Resistance in Overweight and Obese Individuals – A Pilot Study
by: Abhijeet Shelke, et al.
Published: (2024-12-01)

Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms
by: Qing He, et al.
Published: (2008-01-01)

Successful Treatment of Drug-Resistant Seizures Secondary to Ring 20 Mosaicism with Perampanel as an Add-On Antiepileptic Drug
by: Janet Ling, et al.
Published: (2022-01-01)

Commentary: Add a ventricular assist device? Add a stent? A tree of decisions for small univentricular heartsCentral Message
by: Douglas M. Overbey, MD, MPH, et al.
Published: (2022-06-01)